HIV

J&J Ends Mosaico HIV Vaccine Trial on poor Results

Johnson & Johnson’s pharmaceuticals subsidiary Janssen is walking away from plans to launch an HIV vaccine in the immediate future after the data safety monitoring board for its latest Phase 3 trial found that the shot was no better than a placebo.

News

GSK Raises Bet on AIDS Drug with New Shionogi Deal

Top-Feature

Aenova Holding GmbH

Aseptic processing by design: The flexible and efficient use of RABS and Isolators

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

INOSIM GmbH

Predictive Simulation in Pharma Production

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

Evonik (Darmstadt)

Unlocking the value of plastic waste with pyrolysis oil

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

From Catalogue to Collaboration

Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Bayer AG

HIV